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and steps per day. In multivariate analysis, FEV1 and the use of combined inhaled medication were
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Abstract
Purpose Acute exacerbations (AE) in patients with COPD
are associatedwith a decline in lung function, increased risk of
hospitalization, andmortality. In this cross-sectional studywe
tested whether the level of objectively measured daily phys-
ical activity and exercise capacity are associated with the
number of COPD exacerbations.
Methods In 210 patientswithCOPD(67 %men;mean (SD)
age: 63 (8) years) enrolled in The Obstructive Pulmonary
Disease Outcomes Cohort of Switzerland (TOPDOCS)
physical activity (PA) (steps per day, physical activity level,
(PAL)), exercise capacity (6-min walking distance,
(6MWD)), comorbidities, lung function, andmedicationwere
assessed. Differences between COPD patients with frequent
(C2 year) and infrequent (0–1 year) exacerbations were
assessed. Univariate and multivariate analyses were per-
formed to investigate whether the level of objectively
measured daily physical activity and exercise capacity are
associated with the number of COPD exacerbations.
Results Patients with frequent AE had a significantly
lower FEV1 and 6MWD compared to patients with infre-
quent AE. In univariate analysis, the number of exacerba-
tions was inversely associated with FEV1, 6MWD, BMI,
and smoking status while there was a positive association
with RV/TLC and combined inhaled medication. However,
there was no significant association with PAL and steps per
day. In multivariate analysis, FEV1 and the use of com-
bined inhaled medication were independently associated
with the number of AE, after correction for covariates.
Conclusions The findings of this study imply that FEV1,
independent of inhaled medication, is significantly associ-
ated with COPD exacerbations. Neither physical activity
nor exercise capacity was independently associated with
COPD exacerbations.
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Acute exacerbations (AE) of chronic obstructive pulmon-
ary disease (COPD) constitute a substantial burden for
COPD patients. Characterized by a worsening of symptoms
that is beyond the normal day to day variation, AE may
involve admission to hospital, and may lead to death [1].
The symptoms usually include increased dyspnea, cough,
and sputum production [2]. In most COPD patients, AE
become more frequent with progression of COPD. How-
ever, some COPD patients are prone to frequent AE,
whereas other patients with COPD are spared from it [3].
The mechanisms underlying the variation of exacerbation
frequency in COPD patients are currently unknown.
Findings from previous studies suggest associations
between the frequency of AE and a decline in FEV1 [3–8],
worsening of health-related quality of life [3, 4, 9] and
increased mortality [10–12]. Thus, AE are now accepted as
an important outcome measure in COPD and it seems to be
useful to identify those who are at risk for frequent AE in
order to improve disease management and outcome.
The findings of previous studies suggested that an active
lifestyle is an important factor inmaintaininghealth inpatients
with COPD [13–15]. Dyspnea and other symptoms often
contribute to an inactive lifestyle in COPD patients. Further-
more, inactivity leads to atrophy of the skeletal muscles with
development of muscular weakness, which seems to increase
the propensity of exertion to cause dyspnea [16]. Epidemio-
logical studies suggest that physical activity (PA) plays an
important part in the prevention of AE in patients with COPD
[14, 17–19]. However, in these studies PA was assessed by
patient’s records and questionnaires only [14, 19], which is an
important limitation as self-reported PA questionnaires rarely
reflect the actual level of daily PA [20, 21]. A small cross-
sectional study investigated an association between objec-
tively measured PA and exacerbation frequency [22]. How-
ever, lung function was not considered as a confounder.
Thus, the objective of the present study was to investi-
gate the effect of objectively assessed PA and exercise
capacity on the number of COPD exacerbations adjusted
for possible confounders.
Methods
Study Design and Subjects
This study was performed as part of the obstructive pul-
monary disease outcomes cohort of Switzerland (TOP-
DOCS). TOPDOCS is an ongoing prospective, non-
interventional cohort study including COPD patients from
seven study centers in Switzerland. Patients were recruited
during ambulatory visits in the pulmonary clinic or during
hospital stay. The cohort includes male and female sub-
jects, aged between 40 and 75 years, with mild to very
severe COPD (GOLD stages I–IV).
Patients with mental or physical disability precluding
informed consent were excluded from the study. Patients
with an AE within the last 6 weeks were asked to take part
in an exacerbation-free interval.
For the current cross-sectional study, 210 patients were
included between October 2010 and October 2012 at the
seven different study centers in Switzerland.
Ethics Statement
The study was conducted in accordance with the declara-
tion of Helsinki of the World Medical Association, and has
been registered at NCT01527773. Ethical committees of all
participating centers approved the study (cantonal ethics
committees of Zurich (leading center: KEK-ZH-NR:
2011-0106), ethics committee of canton St. Gallen, ethics
committee of canton Thurgau, ethics committee of canton
Basel, and ethics committee of canton Aargau). All sub-
jects gave written informed consent to participate.
Demographics and Medication
Characteristics included age, gender, body mass index
(BMI), smoking status, pack years of smoking (PY),
MMRC (modified medical research council) dyspnea
score, and comorbidities. A detailed patient history
including an interview and review of medical records was
undertaken regarding their use of medication and the pre-
sence of comorbidities. Adherence to described medica-
tions was monitored by patient interviews.
Assessment of Physical Activity and Exercise Capacity
The number of steps per day and the PA level (PAL) were
assessed by a multisensory armband (SenseWear ProTM;
Bodymedia Inc., Pittsburgh, PA, USA) which was worn on
the upper left arm over the triceps muscle. PAL is an
objective measure of daily PA and is defined as the total
energy expenditure divided by the resting metabolic rate
[23]. An inbuilt biaxial accelerometer records the number
of steps per day [24].
Patient’s data were recorded over a period of 7 con-
secutive days. The threshold for valid data from the mul-
tisensory armband was set at 4 days with a minimum of
22.5 h/day. In total, 178 patients had complete PA data. 22
of the 210 patients were excluded from the analysis due to
technical reasons, and 10 patients were excluded because
they wore the armband less than 4 days.
Exercise capacity was assessed by measuring the 6-min
walking distance (6MWD) according to American thoracic
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society (ATS) guidelines [25]. The patients did not practice
the 6MWT before the actual study assessment.
Exacerbation Frequency
The patients were asked about the number of AE during the
preceding year. AE was defined as an event which led to
prescription of antibiotics and/or corticosteroids [26].
Patients with infrequent exacerbations were considered to
have 0–1 AE per year, whereas patients with C2 AE per
year were defined as frequent exacerbators [3]. In 141
patients, a follow-up visit one year after baseline exami-
nation was analyzed to verify the consistency of exacer-
bation frequency. Evaluation of exacerbation history
followed the same standards as during the baseline
examination.
Lung Function
All patients underwent standard pulmonary function testing
according to ATS guidelines [27] to measure forced expi-
ratory volume in one second (FEV1), residual volume
(RV), and total lung capacity (TLC).
Blood Analysis
Daytime arterial blood gas analysis was performed with an
ABL 700 series blood gas analyzer (Radiometer Copen-
hagen) to measure partial oxygen pressure (PaO2) and
partial carbon dioxide pressure (PaCO2).
Data Analysis and Statistics
All results are shown as median values and quartiles unless
otherwise stated. Statistical analysis was performed with
Statistica V6.0 (StatSoft, Tulsa, OK, USA) and STATA 12
(StataCorp, Texas, USA). Differences between COPD
patients with frequent exacerbations and patients with
infrequent exacerbations regarding PA, exercise capacity,
respiratory variables, and medication were assessed by
Wilcoxon rank-sum test, independent t test, and v2 tests.
Univariate regression analysis was used to investigate
associations between the number of AEs during the most
recent year (dependent variable) and respiratory variables,
PA (steps per day and PAL), exercise capacity (6MWD), as
well as medications (independent variables). Furthermore,
in those patients who had available follow-up visit data one
year after the baseline examination univariate regression
analysis was performed to investigate the association
between PA (steps per day and PAL) and the number of AE
occurring in the year after the baseline examination. Mul-
tivariate regression analysis included all variables with a
p value of less than 0.1 in univariate analysis. A p value of
\0.05 was considered to be statistically significant.




Of the 277 patients assessed for eligibility 210 entered the
study (Fig. 1). Patient characteristics are shown in Table 1.
15 Patients (7 %) were in GOLD stage I, 69 patients
(33 %) in GOLD II, 74 patients (35 %) in GOLD III, and
52 patients (25 %) in GOLD stage IV. Considering the
revised GOLD classification, 52 % of the infrequent ex-
acerbators were in group GOLD D compared to 95 % of
the frequent exacerbators. In total there were 236 exacer-
bations, 50 of them led to hospital admissions. In general,
the level of daily PA was low (median PAL 1.4 (1.3/1.6))
with no influences of seasonality (median PAL spring/
summer 1.4 (1.3/1.6) versus median PAL autumn/winter
1.4 (1.3/1.6), p = 0.713).
Comparison of Patients with Frequent and Infrequent
Exacerbations
The comparison of patients with frequent and infrequent
exacerbations is shown in Table 1. Patients with frequent
AE had a significantly lower 6MWD, FEV1, and a signif-
icantly higher RV/TLC compared to patients with infre-
quent exacerbations.
The distribution of steps per day, PAL, and 6MWD
regarding frequent and infrequent exacerbators is shown in
Fig. 2. As displayed in Fig. 2, only 6MWD differed sig-
nificantly between infrequent and frequent exacerbators.
Univariate Regression Analysis Evaluating
Determinants of Exacerbation Frequency
Exercise capacity assessed by the 6MWD-test was signif-
icantly inversely associated with the number of AE. The
number of steps per day was borderline negatively asso-
ciated with the number of AE. There was no statistically
significant association between the number of AE and PAL
(Table 2). In 141 patients who had a follow-up visit one
year after the baseline examination the results of the uni-
variate analysis remained unchanged.
Furthermore, the number of AE was inversely associated
with BMI, smoking status, and FEV1. RV/TLC as well as
combined inhalation of steroids/long-acting beta-agonists/
long-actingmuscarinic-antagonists (LAMA ? LABA ? GC)
showed a significant association (Table 3).
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Multiple Regression Model of all Postulated Predictors
Table 3 shows the results of a multiple regression model
including potential predictors with a univariate p value of
\0.1. Because of an interrelationship between RV/TLC
and FEV1 (r = -0.76, p\ 0.001), RV/TLC was removed
from the model. 6MWD did not remain significantly
associated with the number of AE after correction for BMI,
smoking status, FEV1, use of beta blockers, combined
inhalation of LAMA ? LABA ? GC, and steps per day.
In the final model, FEV1 and combined inhalation of
LAMA ? LABA ? GC were the only factor indepen-
dently associated with the number of AE. In consideration
of residual assumptions, the model was further validated
after square root transformation and the results remained
unchanged.
Discussion
This study investigated if objectively measured PA and
exercise capacity have an independent effect on the number
of AE in patients with COPD. The findings of this study
imply that both PA and exercise capacity have no inde-
pendent effect on the number of AE. Only the severity of
airflow obstruction, measured by FEV1, and the use of
combined bronchodilators (LAMA ? LABA ? GC) were
independently associated with AE in COPD patients.
There is preliminary evidence that a high level of PA is
associated with a reduced risk of admission to hospital and
mortality [14, 17, 19]. However, in these studies [14, 17,
19] PA was assessed by patient’s records and question-
naires only. Garcia-Aymerich et al. [17] found that a rel-
atively high level of PA, which was defined as C60 min
walking/day, reduced the risk of admission to hospital due
to an exacerbation by nearly 50 %. Furthermore, Garcia-
Aymerich et al. [14] suggested that a level of PA equiva-
lent to walking or cycling for 2 h/week or more is asso-
ciated with a lower risk of admissions to hospital and
mortality in COPD patients. Donaldson et al. [19] exam-
ined the patient’s time spent outside their home in a lon-
gitudinal study including 147 COPD patients. Patients
suffering from frequent exacerbations were more likely to
become housebound, and patients with little outdoor
activity had a greater risk of being hospitalized due to AE
[19]. However, considerable differences between objective
assessment and questionnaires have been reported. In
general, questionnaires tend to overestimate PA when
compared to objectively measured data [24, 28, 29].
Therefore, we considered two objectively assessed PA
outcomes, steps per day and PAL measured during at least
4 days with a minimum of 22.5 h/day. Watz et al. [30]
Fig. 1 Study flow
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showed that a time frame of 2–3 days is sufficient to reli-
ably assess PA in patients with severe COPD, whereas
5 days seem to be required in mild COPD. However, the
association between PAL and the number of AE was not
significant after correcting for covariates, neither was the
association with steps per day. In contrast to our study,
Waschki et al. [22] found in a study which included 134
COPD patients and 46 healthy controls significant associ-
ations between both, steps per day and PAL (dependent
variables) and an exacerbation rate of[1 in the preceding
Table 1 Comparison between
patients with frequent and
infrequent exacerbations
Values are median (quartiles) or
mean (SD) unless otherwise
stated
BMI body mass index, MMRC
modified medical research
council, CAD coronary artery
disease, FEV1 Post forced
expiratory volume in one
second after dilatation, RV/TLC
residual volume to total lung
capacity, PaO2 partial pressure
for oxygen, PaCO2 partial












N = 210 N = 152 N = 58
Characteristics
Age, y 63 (57/68) 64 (58/69) 63 (57/68) 0.281
Male/female 139/71 104/48 35/23 0.269
BMI, kg/m2 26.5 (22.4/28.9) 26.5 (22.5/30.0) 24.4 (21.6/27.6) 0.036
Current smokers, N (%) 51 (24) 42 (28) 9 (16) 0.067
Pack years of smoking, N 40 (25/60) 40 (27/60) 37 (24/52) 0.104
MMRC dyspnea score, N 1.9 (1.1) 1.7 (0.1) 2.4 (0.1) \0.001
GOLD A 24 (11) 24 (16) 0 (0) \0.001
GOLD B 43 (21) 42 (28) 1 (2) \0.001
GOLD C 8 (4) 6 (4) 2 (3) 0.613
GOLD D 134 (64) 79 (52) 55 (95) \0.001
Comorbidities
Arterial hypertension, N (%) 100 (48) 77 (51) 23 (40) 0.154
CAD, N (%) 39 (19) 29 (19) 10 (17) 0.760
Diabetes, N (%) 25 (12) 21 (14) 4 (7) 0.166
Osteoporosis, N (%) 25 (12) 21 (14) 4 (7) 0.166
Respiratory variables
FEV1 post, % pred. 41.5 (30.0/63.0) 46.0 (32.0/65.5) 32.5 (25.0/45.0) \0.001
RV/TLC, % 57.0 (47.5/65.0) 55.0 (45.5/63.0) 61.0 (52.0/68.0) 0.013
PaO2, kPa 9.0 (8.1/10.0) 9.0 (8.0/10.0) 9.2 (8.1/10.1) 0.502
PaCO2, kPa 5.1 (4.7/5.5) 5.1 (4.7/5.4) 5.0 (4.6/5.5) 0.650
Medication
Antihypertensives, N (%) 101 (48) 77 (51) 24 (41) 0.229
Statins, N (%) 64 (30) 53 (35) 11 (19) 0.025
Beta blockers, N (%) 43 (20) 38 (25) 5 (9) 0.009
LABA, N (%) 3 (1) 3 (2) 0 (0) \0.001
LABA ? GC, N (%) 32 (15) 25 (16) 7 (12) 0.003
LAMA, N (%) 12 (6) 11 (7) 1 (2) \0.001
LAMA ? GC, N (%) 8 (4) 5 (3) 3 (5) \0.001
LAMA ? LABA, N (%) 28 (13) 18 (12) 9 (16) \0.001
LAMA ? LABA ? GC,
N (%)
119 (57) 72 (47) 47 (81) \0.001
Acute Exacerbations
Average number of AE per
year
1 (0/2) 0 (0/1) 3 (2/3) \0.001
Exercise capacity
6-min walking distance, m 405 (135) 420.0 (131.9) 366.1 (134.5) 0.010
Physical activity
Physical activity level 1.4 (1.3/1.6) 1.4 (1.3/1.6) 1.4 (1.3/1.6) 0.472
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year. However, in the multivariate regression analyses,
adjustment was only performed for age, gender, study site,
and BMI[ 30, but not for lung function parameters. Fur-
thermore, the minimal clinical important difference of PAL
is unknown, therefore, a formal power analysis would not
be evidence based. However, if there was a consistent
Fig. 2 The distribution of steps per day, PAL, and 6MWD in
frequent and infrequent exacerbators is illustrated
Table 2 Univariate regression analysis evaluating the association
between the number of acute exacerbations during the most recent
year and patient characteristics




Age, y 0.00 -0.02/0.03 0.789
Male/female -0.37 -0.80/0.06 0.095
BMI, kg/m2 -0.04 -0.07/-0.01 0.015
Current smokers, N -0.58 -1.05/-0.11 0.017
Pack years of smoking, N -0.00 -0.01/0.00 0.474
Comorbidities
Arterial hypertension, N -0.10 -0.51/0.31 0.622
CAD, N -0.15 -0.68/0.37 0.570
Diabetes, N -0.50 -1.13/0.13 0.116
Depression, N -0.05 -0.68/0.58 0.877
Respiratory variables
FEV1 post, % pred. -0.03 -0.03/-0.02 \0.001
RV/TLC, % 0.03 0.02/0.05 \0.001
PaO2, kPa -0.03 -0.17/0.10 0.601
PaCO2, kPa -0.00 -0.30/0.30 0.988
Medication
Antihypertensives, N 0.03 -0.38/0.44 0.891
Statins, N -0.38 -0.82/0.06 0.092
Beta blockers, N -0.45 -0.95/0.06 0.081
LABA, N -1.14 -2.86/0.58 0.193
LABA ? GC, I -0.33 -0.90/0.24 0.254
LAMA, N -0.66 -1.54/0.22 0.139
LAMA ? GC, N 0.78 -0.29/1.85 0.150
LAMA ? LABA, N 0.31 -0.29/0.91 0.310








Physical activity level -0.11 -0.98/0.76 0.808
Steps per day, N -0.00 -0.00/0.00 0.060
BMI body mass index, CAD coronary artery disease, FEV1 Post
forced expiratory volume in one second after dilatation, RV/TLC
residual volume to total lung capacity, PaO2 partial pressure for
oxygen, PaCO2 partial pressure for carbon dioxide, LABA long-acting
beta-agonist, LAMA long-acting muscarinic-antagonist, GC
glucocorticoids
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association between PA and exacerbation rate we would
have expected to reproduce the findings of the considerably
smaller study by Waschki et al. [22]. These contrasting
findings may thus be explained by the fact that we also
included FEV1 as a covariate in the multivariate analysis.
Another reason why our findings differ from those of
Waschki et al. [22] may be that in their study COPD
exacerbations were defined as exacerbations based on
either the decision by a patient’s primary clinician or by
study personnel without any specific criteria that had to be
met for the definition of an exacerbation.
Although we could demonstrate an association between
the 6MWD and the number of AE in univariate regression
analysis, this association did not remain significant after
correction for covariates. However, when comparing fre-
quent and infrequent exacerbators, there are previous
studies which demonstrated significant differences between
patients with frequent and infrequent exacerbations con-
cerning the 6MWD [6, 31]. In a study including 205
patients with COPD, Cote et al. [6] found patients with
frequent exacerbations to walk significantly less far
(334 ± 117 m) compared to infrequent exacerbators
(385 ± 116 m, p = 0.006) during the 6MWD. Further-
more, the findings of a small study including 60 patients
with COPD suggest that AE are associated with reductions
in functional exercise capacity measured by 6MWD [31].
These results confirm our findings that COPD patients with
frequent AE had a significantly lower 6MWD compared to
infrequent exacerbators (Table 2).
The different results on PA and exercise capacity may
represent two different aspects of activity. While PA rep-
resents what people do during daily routine, exercise
capacity represents what people could do [32].
We found an inverse relationship between the severity
of airflow limitation and the frequency of AE. These results
confirm the findings of previous studies [3–8]. Further,
only the use of combined inhalation of LAMA ? LA-
BA ? GC was also independently associated with exac-
erbation frequency. Our interpretation of this finding is that
patients with more severe disease are more likely to receive
combined inhaled medication. Since the efficacy of inhaled
steroids on the prevention of AE is considerably low and a
matter of current discussion [33] we think that the associ-
ation between exacerbation frequency and disease severity
predominates the potential preventive effect of GC on
exacerbation.
The main limitation of our study is the cross-sectional
design that does not allow establishing a causal relationship
between PA and the number of AE. Further, due to the
study design, we cannot determine whether PA influences
exacerbation frequency or exacerbation frequency influ-
ences PA. Either a randomized controlled trial or a pro-
spective cohort study would provide stronger evidence; in
the latter case a temporal relationship as a possible element
of causal interference may be determined. A further limi-
tation of the study is that the lack of an independent
association between PA and exacerbation frequency might
also be due to insufficient power of the study. The use of
formal exacerbation diary cards might have identified
additional unreported exacerbations.
In conclusion, the findings of the current study underpin
preliminary data that the severity of airflow obstruction,
independent of inhaled medication, is significantly associ-
ated with the number of AE in COPD patients. The level of
daily PA and exercise capacity seems to have no inde-
pendent effect on the number of AEs in patients with
COPD.
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